Vandetanib (Caprelsa®) for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
Rapid Review
| Commenced | Completed | Outcome |
| 06/06/2013 | 03/07/2013 | Full Pharmacoeconomic Evaluation Recommended |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.